AbbVie (NYSE:ABBV) Shares Climb 1.4% After Analyst Upgrade

Shares of AbbVie Inc. (NYSE:ABBV) traded up 1.4% during mid-day trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $285.00 to $300.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. AbbVie traded as high as $277.60 and last traded at $276.2410. 4,262,959 shares changed hands during trading, a decline of 34% from the average session volume of 6,418,698 shares. The stock had previously closed at $272.42.

Other analysts also recently issued reports about the stock. Oppenheimer boosted their target price on shares of AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. UBS Group upped their price target on AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research report on Tuesday. Cantor Fitzgerald increased their price objective on AbbVie from $285.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Barclays raised their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $277.18.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen AbbVie’s oncology pipeline. The FDA granted two Breakthrough Therapy designations to Temab-A (telisotuzumab adizutecan) for colorectal cancer and non-small cell lung cancer. The designation can accelerate development and regulatory review, although it does not guarantee approval or commercial success. AbbVie’s Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
• Positive Sentiment: Analysts raised their valuation targets. JPMorgan increased its target to $300 and maintained an overweight rating, while Cantor Fitzgerald lifted its target to $290 and Guggenheim reaffirmed a buy rating with a $288 target. These actions suggest analysts see additional upside from AbbVie’s growth products and pipeline. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Positive Sentiment: New products are more than offsetting Humira’s patent-loss decline. Humira revenue fell 35.9% to $756 million, but total quarterly revenue rose 10.2% to $16.99 billion. The performance indicates that immunology, neuroscience and other newer medicines are successfully replacing the former blockbuster. AbbVie Outgrew Humira’s Collapse
• Neutral Sentiment: Valuation and income appeal remain part of the debate. AbbVie’s dividend and defensive characteristics may attract income-focused investors, but the stock’s elevated valuation means continued earnings and pipeline execution are important to justify further gains. Treasury Bills or Dividend Stocks

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Riversedge Advisors LLC increased its holdings in AbbVie by 1.8% in the third quarter. Riversedge Advisors LLC now owns 4,748 shares of the company’s stock worth $1,242,000 after buying an additional 82 shares during the last quarter. Wedmont Private Capital lifted its stake in AbbVie by 12.5% in the third quarter. Wedmont Private Capital now owns 49,199 shares of the company’s stock valued at $13,403,000 after acquiring an additional 5,468 shares during the last quarter. Intelligence Driven Advisers LLC grew its position in AbbVie by 23.2% in the third quarter. Intelligence Driven Advisers LLC now owns 1,477 shares of the company’s stock worth $386,000 after acquiring an additional 278 shares in the last quarter. Athena Wealth Management LLC increased its stake in shares of AbbVie by 10.8% during the 3rd quarter. Athena Wealth Management LLC now owns 4,167 shares of the company’s stock worth $1,090,000 after purchasing an additional 406 shares during the last quarter. Finally, Central Bank & Trust Co. raised its holdings in shares of AbbVie by 2.3% during the 3rd quarter. Central Bank & Trust Co. now owns 11,271 shares of the company’s stock valued at $2,948,000 after purchasing an additional 254 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 1.4%

The business’s fifty day moving average price is $258.56 and its two-hundred day moving average price is $236.35. The firm has a market cap of $488.06 billion, a P/E ratio of 78.03, a P/E/G ratio of 1.23 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business posted $2.97 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts predict that AbbVie Inc. will post 14.01 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s payout ratio is 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.